Adalimumab weekly vs placebo
Adalimumab weekly showed no clear difference in frequency of treatment discontinuation compared with placebo (moderate certainty).
- RR 5 [0.25, 101.63]1 study · 102 participantsModerate
Adalimumab weekly showed no clear difference in frequency of treatment discontinuation compared with placebo (moderate certainty).
Topical foscarnet showed no clear difference in adverse effects during use of the preventative intervention (leading… compared with placebo (moderate certainty).
It is very uncertain whether FAE changes common nuisance AEs (not leading to treatment discontinuation) compared with MTX (very low certainty).
FAE probably leads to higher common nuisance AEs (not leading to treatment discontinuation) compared with placebo (moderate certainty).
It is very uncertain whether FAE changes AEs leading to treatment discontinuation compared with MTX (very low certainty).
Imiquimod 5% cream with tazarotene 0.1% gel showed no clear difference in secondary outcome: Discontinuation of treatment because of harms… compared with imiquimod 5% cream alone (low certainty).